Tech Company Financing Transactions
VistaGen Therapeutics Funding Round
VistaGen Therapeutics closed a $4.8 million funding round on 9/24/2018. Backers included private investors.
Transaction Overview
Company Name
Announced On
9/24/2018
Transaction Type
Venture Equity
Amount
$4,778,750
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 33 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
343 Allerton Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
VistaGen Therapeutics is a biopharmaceutical company pioneering the use of embryonic stem cells (ES cells) for drug discovery and development and predictive toxicology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shawn Singh
Chief Financial Officer
Jerrold Dotson
Chief Medical Officer
Mark Smith
Chief Scientific Officer
Ralph Snodgrass
Browse more venture capital transactions:
Prev: 9/24/2018: Tvardi Therapeutics venture capital transaction
Next: 9/24/2018: Citybase venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs